SCHEMBL3685346

SCHEMBL3685346

CCOCCc1cccn(-c2ccc(N)cc2C)c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.35
F2 P00734 4/20 0.35
F10 P00742 4/20 0.35
ALDH1A1 P00352 4/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
KDM4E B2RXH2 3/20 0.35
THRB P10828 2/20 0.35
LMNA P02545 2/20 0.35
ALOX15 P16050 2/20 0.35
GAA P10253 3/20 0.35
RAD52 P43351 1/20 0.35
GFER P55789 1/20 0.35
NR4A1 P22736 1/20 0.33
PTK2B Q14289 1/20 0.33
BRPF1 P55201 1/20 0.32
HPGD P15428 2/20 0.32
HSD17B10 Q99714 2/20 0.32
POLB P06746 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3675202 0.88 F2 (0.38) MAPTF2F10ALDH1A1MEN1
SCHEMBL3643269 0.82 ALDH1A1 (0.40) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL2473536 0.81 F2 (0.48) MAPTF2F10ALDH1A1MEN1
SCHEMBL2475744 0.78 SMYD2 (0.34) MAPTF2F10ALDH1A1MEN1
SCHEMBL3640060 0.76 BRPF1 (0.33) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL3676961 0.73 NR4A1 (0.43) MAPTALDH1A1KDM4ELMNAGAA
SCHEMBL3686796 0.73 NR4A1 (0.44) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL2471740 0.72 F2 (0.39) F2F10ATAD2
SCHEMBL3423017 0.71 MAPT (0.33) MAPTF2ALDH1A1MEN1KMT2A
SCHEMBL14924782 0.70 COMT (0.46) MAPTF2F10ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
EP-2167499-B1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Pharma AG (DE) 2011-12-14 EP disclosed
EP-2167499-B1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Pharma AG (DE) 2011-12-14 EP disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
EP-2167499-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Schering Pharma AG (DE) 2010-03-31 EP disclosed
WO-2008155069-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed
WO-2008155069-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, OXA1L, PPOX MAPT 4810/4885F2 46/4885F10 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.